Domov › Rakovina močového mechúra › Texas › Dallas
Klinické štúdie Rakovina močového mechúra v meste Dallas, TX
27 štúdií pre Rakovina močového mechúra hľadá účastníkov v zariadeniach v meste Dallas a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Prebieha náborFáza 2
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
Prebieha náborFáza 1/2
- UT Southwestern Medical Center, Dallas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Prebieha náborFáza 2
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Prebieha náborFáza 1
- Cancer Center Outpatient Building, Dallas
- The University of Texas Southwestern Medical Center, Dallas
- UT Southwestern Medical Center - West Campus Building, Dallas
- a 2 ďalších
DESTINY-PANTUMOUR04
Prebieha náborObservačná štúdia
- Research Site, Dallas
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Prebieha náborFáza 3
- Parkland Health and Hospital System, Dallas
- UT Southwestern Medical Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Prebieha náborObservačná štúdia
- UT Southwestern Medical Center, Dallas
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Prebieha náborFáza 2
- Urology Clinics of North Texas, PLLC, Dallas
- UT Southwestern Medical Center, Dallas
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Prebieha náborObservačná štúdia
- University of Texas Southwestern Medical Center, Dallas
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Prebieha náborFáza 1
- University of Texas Southwestern, Dallas
- Texas Oncology, P.A, Dallas
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Prebieha náborFáza 2/3
- Research Site, Dallas
Measuring Surgical Recovery After Radical Cystectomy
Prebieha náborObservačná štúdia
- University of Texas - Southwestern, Dallas
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Prebieha náborFáza 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Prebieha náborFáza 1/2
- UT Southwestern Medical Center, Dallas
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Prebieha náborFáza 2
- Baylor Scott & White Research Institute, Dallas
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Prebieha náborFáza 3
- Research Site, Dallas
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Prebieha náborFáza 2
- Baylor Scott and White Research Institute, Dallas
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Prebieha náborFáza 1
- NEXT Dallas, Dallas
Predicting BCG Response
Prebieha náborObservačná štúdia
- University of Texas Southwestern, Dallas
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Prebieha nábor
- UT Southwestern Medical Center, Dallas
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
Prebieha náborObservačná štúdia
- UT Southwestern Medical Center, Dallas
Bladder Cancer Screening Trial
Prebieha nábor
- University of Texas Southwestern Medical Center, Dallas
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1/2
- NEXT Oncology - Dallas, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Prebieha náborFáza 1
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Prebieha náborObservačná štúdia
- UT Southwestern Medical Center at Dallas, Dallas
Blue Light Cystoscopy With Cysview® Registry
Prebieha náborObservačná štúdia
- UT Southwestern, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Prebieha náborObservačná štúdia
- Massive Bio SYNERGY-AI site, Dallas
Štúdie Rakovina močového mechúra v iných mestách
- New York City, NY35 štúdií
- Nashville, TN31 štúdií
- Houston, TX31 štúdií
- Boston, MA26 štúdií
- Washington, DC26 štúdií
- Los Angeles, CA24 štúdií
- Baltimore, MD24 štúdií
- St. Louis, MO22 štúdií
- Philadelphia, PA21 štúdií
- Seattle, WA21 štúdií
- Edison, NJ21 štúdií
- Chicago, IL21 štúdií
Iné štúdie v Dallas
- Rakovina prsníka55 štúdií
- Nemalobunkový karcinóm pľúc52 štúdií
- Metastatická rakovina42 štúdií
- Srdcové zlyhanie42 štúdií
- Rakovina (všetky typy)37 štúdií
- Rakovina prostaty36 štúdií
- Kolorektálny karcinóm33 štúdií
- Obézita30 štúdií
- Rakovina vaječníkov28 štúdií
- Rakovina pľúc27 štúdií
- Rakovina endometria24 štúdií
- Kardiovaskulárne ochorenia23 štúdií
Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.